Dr. Kerkar also served as the Co-Chair for the NIH Clinical Fellows’ Committee and received a NIH Clinical Center’s leadership award. The NIH Clinical Center is recognized as the largest institution in the United States devoted entirely to clinical research. Dr. Kerkar provided care for patients enrolled in numerous innovative first-in-human clinical protocols. He completed a residency in anatomic pathology at the National Institutes of Health with a surgical pathology fellowship at the Mayo Clinic, Rochester, Minnesota. He has authored over 50 manuscripts and abstracts in high-impact journals such Cell, JCI, Blood, Cancer Research, and Frontiers in Immunology and holds a Google H-Index of 26.
He currently serves as the Associate Editor of T cell Biology at Frontiers in Immunology.
Dr. Kerkar started his executive career in industry at Bristol Myers Squib as an associate director of pathology and provided immuno-oncology and digital/computational pathology expertise for evaluation of PDL1 and other biomarkers in Nivolumab combination clinical trials. He was then recruited to Boehringer-Ingelheim Pharmaceuticals to become a distinguished research fellow and executive member of the global cancer immunology leadership team. He recruited, trained and managed a diverse scientific team that provided target discovery and biomarker support for multiple cancer immunotherapy programs. The biomarker team characterized cell expression patterns through the use of image analysis for DLL3, B7H6, Trop2 in addition to other important targets for bi-specific T cell engager programs. He was then recruited to Eli Lilly & Company as associate vice president to oversee translational efforts in immuno-oncology and efficiently pivoted to provide medical leadership to aurora kinase inhibitor-based trials during the COVID pandemic and designed a window-of-opportunity study, EMBER 2, for Imlunestrant, an oral SERD. In Nov. 2020, Dr. Kerkar joined Exuma Biotech to oversee research and development in West Palm Beach, Florida. During his 4 years with the company, the R&D team developed a novel same-day subcutaneous CAR-T manufacturing platform and an innovative in-vivo gene therapy CAR-T program. The team delivered multiple data presentations at international meetings including AACR, SITC, NCI Cancer Immunology Conferences, and CAR-TCR conferences.
In August 2024, Sid launched Kerkar Consulting LLC, a business aimed at providing expert support to biotech, pharmaceutical companies, academic institutions, non-profit organizations, and individual patients interested in developing or learning about biologics.
Sid Kerkar - Google Scholar
Contact: Email: sidharth@kerkarconsulting.com
